Condition(s) treated: Acne

Intervention: Doxycycline (Drug); Azithromycin (Drug)

Phase: Phase 2

Enrollment status: Recruiting

Sponsor: Shaheed Beheshti Medical University

Principal investigator(s) or official(s):
Parviz Toossi, M.D., Study Chair, Affiliation: Skin Research Center
Hamideh Moravvej, M.D., Principal Investigator, Affiliation: Skin Research Center
Akbar Mousazadeh halim, M.D., Principal Investigator, Affiliation: Skin Research Center

Overall contact:
Parviz Toossi, M.D., Phone: 98-21-22744393, Ext: 5, Email: src@sbmu.ac.ir

a comparison of efficacy and adverse side effects occurrence of Doxycycline and Azithromycin in the management of moderate acne vulgaris

Official title: the Comparison Efficacy of Azithromycin With Doxycycline in the Treatment of Acne Vulgaris

Study design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study

Primary outcome: change in acne lesions (Time Frame: 12 weeks)

Secondary outcome: global response rates, patient's own assessment, side effects and compliance (Time Frame: 12 weeks)

Minimum eligible age: 18 Years. Maximum eligible age: 30 Years. Eligible gender(s): Both.

Criteria:

Inclusion Criteria:

- Between 18 to 30 year old

- Moderate facial Acne(At least 10 inflammatory lesions with maximum 3 nodules and

pseudocysts

Exclusion Criteria:

- Pregnancy

- Breast Feeding

- Acne Fulminant

- Acne conglobate

- Isotretinoin therapy within past 6 months

- topical treatment in last 2 weeks

- use of systemic antibiotic in the last month

- Hyperandrogenism symptoms

- Menstrual irregularity

Parviz Toossi, M.D., Phone: 98-21-22744393, Ext: 5, Email: src@sbmu.ac.ir

Shaheed Beheshti Medical University, Skin research center, Tehran 198994148, Iran, Islamic Republic of; Recruiting

Start date: August 2006
End date: February 2008
Last updated: January 28, 2008

Web SmartSkinCare.com